Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{d9abf42df98d439cb79e0c6e44db5877,
title = "Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis",
abstract = "Objectives: Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1-2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration.Design and methods: Fifty-five stool samples were analyzed by the IBDoc{\circledR} Calprotectin Home Testing kit and the B{\"U}HLMANN fCAL{\circledR} turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated.Results: We found a strong correlation coefficient of 0.887 between FC measured on IBDoc{\circledR} and the laboratory assay B{\"U}HLMANN fCAL{\circledR} turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3-5.5{\%} (B{\"U}HLMANN fCAL{\circledR} turbo) and in the range of 4.8-26.6{\%} (IBDoc{\circledR}).Conclusions: This study suggests that IBDoc{\circledR} is a suitable alternative for the assessment of disease activity in IBD patients.",
keywords = "Journal Article",
author = "Julie Hejl and Klaus Theede and Brian M{\o}llgren and Madsen, {Kirsten Vikkels{\o}} and Ashraf Heidari and {{\'A} Steig}, Anna and Mogens Fenger",
year = "2018",
month = "3",
doi = "10.1016/j.plabm.2017.11.002",
language = "English",
volume = "10",
pages = "10--14",
journal = "Practical Laboratory Medicine",
issn = "1530-7085",
publisher = "Wiley-Blackwell Publishing, Inc",

}

RIS

TY - JOUR

T1 - Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

AU - Hejl, Julie

AU - Theede, Klaus

AU - Møllgren, Brian

AU - Madsen, Kirsten Vikkelsø

AU - Heidari, Ashraf

AU - Á Steig, Anna

AU - Fenger, Mogens

PY - 2018/3

Y1 - 2018/3

N2 - Objectives: Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1-2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration.Design and methods: Fifty-five stool samples were analyzed by the IBDoc® Calprotectin Home Testing kit and the BÜHLMANN fCAL® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated.Results: We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3-5.5% (BÜHLMANN fCAL® turbo) and in the range of 4.8-26.6% (IBDoc®).Conclusions: This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

AB - Objectives: Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1-2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration.Design and methods: Fifty-five stool samples were analyzed by the IBDoc® Calprotectin Home Testing kit and the BÜHLMANN fCAL® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated.Results: We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3-5.5% (BÜHLMANN fCAL® turbo) and in the range of 4.8-26.6% (IBDoc®).Conclusions: This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

KW - Journal Article

U2 - 10.1016/j.plabm.2017.11.002

DO - 10.1016/j.plabm.2017.11.002

M3 - Journal article

VL - 10

SP - 10

EP - 14

JO - Practical Laboratory Medicine

JF - Practical Laboratory Medicine

SN - 1530-7085

ER -

ID: 52170403